Dummer Reinhard
Department of Dermatology, University Hospital of Zürich, Gloriastrasse 31, CH-8091 Zürich, Switzerland.
Expert Opin Emerg Drugs. 2005 May;10(2):381-92. doi: 10.1517/14728214.10.2.381.
Cutaneous T-cell lymphomas are a heterogeneous group of rare lympho-proliferative disorders. In most cases, they are characterised by the accumulation of clonal CD4+ lymphocytes in the skin. Extracutaneous involvement is present in late stages only. Unfortunately, only few drugs are registered for these disfiguring diseases. Skin-directed therapies using topical formulations are the preferred first-line modalities for cutaneous lesions in early stages. In this field there are interesting developments using topical retinoids and gene therapy products, such as adeno-IFN-gamma. Systemic treatment uses biologicals, such as fusion molecules, monoclonal antibodies and immune response modifiers (IFNs, retinoids), and well-tolerated antiproliferative drugs, such as histone deacetylase inhibitors or liposomal doxorubicin.
皮肤T细胞淋巴瘤是一组异质性的罕见淋巴增殖性疾病。在大多数情况下，其特征是皮肤中克隆性CD4+淋巴细胞的积聚。仅在晚期出现皮肤外受累。不幸的是，仅有少数药物被注册用于这些毁容性疾病。使用局部制剂的皮肤定向疗法是早期皮肤病变的首选一线治疗方式。在该领域，使用局部维甲酸和基因治疗产品（如腺病毒-γ干扰素）有一些有趣的进展。全身治疗使用生物制剂，如融合分子、单克隆抗体和免疫反应调节剂（干扰素、维甲酸），以及耐受性良好的抗增殖药物，如组蛋白去乙酰化酶抑制剂或脂质体阿霉素。
